Table of Contents Author Guidelines Submit a Manuscript
Sarcoma
Volume 2010 (2010), Article ID 317462, 14 pages
http://dx.doi.org/10.1155/2010/317462
Guidelines

UK Guidelines for the Management of Bone Sarcomas

1Royal Orthopaedic Hospital, Birmingham B31 2AP, UK
2Nuffield Orthopaedic Centre, Oxford OX3 7LD, UK
3Freeman Hospital, Newcastle-upon-Tyne NE7 7DN, UK
4The Royal Marsden, Sutton SM2 5PT, UK
5Leeds Teaching Hospitals, LS9 7TF, UK
6Birmingham Children’s Hospital, B4 6NH, UK
7Queen Elizabeth Hospital, Birmingham B15 2TH, UK
8University College Hospital, London NW1 2BU, UK

Received 10 September 2010; Accepted 20 October 2010

Academic Editor: Ole Nielsen

Copyright © 2010 Robert Grimer et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. National Comprehensive Cancer Network, “NCCN National Clinical Practice Guidelines in Oncology,” Version 2, 2010, http://www.ncccn.org/.
  2. S. Bielack, D. Carrle, and P. G. Casali, “Osteosarcoma: ESMO clinical recommendations for diagnosis, treatment and follow-up,” Annals of Oncology, vol. 20, supplement 4, pp. iv137–iv139, 2009. View at Publisher · View at Google Scholar
  3. M. Paulussen, S. Bielack, H. Jürgens, and P. G. Casali, “Ewing's sarcoma of the bone: ESMO clinical recommendations for diagnosis, treatment and follow-up,” Annals of Oncology, vol. 20, supplement 4, pp. iv140–iv142, 2009. View at Publisher · View at Google Scholar
  4. P. C. W. Hogendoorn, “Bone sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow up,” Annals of Oncology, vol. 21, supplement 5, pp. v200–v209, 2010. View at Google Scholar
  5. D. J. Cook, G. H. Guyatt, A. Laupacis et al., “Rules of evidence and clinical recommendations on the use of antithrombotic agents,” Chest, vol. 102, no. 4, supplement, pp. 305S–311S, 1992. View at Google Scholar
  6. A. V. Maheshwari and E. Y. Cheng, “Ewing sarcoma family of tumours,” Journal of American Academy of Orthopaedic Surgeons, vol. 18, no. 2, pp. 94–107, 2010. View at Google Scholar
  7. P. J. Messerschmitt, R. M. Garcia, F. W. Abdul-Karim, E. M. Greenfield, and P. J. Getty, “Osteosarcoma,” Journal of the American Academy of Orthopaedic Surgeons, vol. 17, no. 8, pp. 515–527, 2009. View at Google Scholar · View at Scopus
  8. National Institute for Health and Clinical Excellence (NICE), “Guidance on Cancer Services—Improving Outcomes for People with Sarcoma: the Manual [Needs assessment, Evidence review, List of recommendations],” 2006, (Developed by the National Collaborating Centre for Cancer).
  9. L. Mirabello, R. J. Troisi, and S. A. Savage, “International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons,” International Journal of Cancer, vol. 125, no. 1, pp. 229–234, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. C. A. Stiller, A. W. Craft, and I. Corazziari, “Survival of children with bone sarcoma in Europe since 1978: results from the EUROCARE study,” European Journal of Cancer, vol. 37, no. 6, pp. 760–766, 2001. View at Publisher · View at Google Scholar
  11. H. J. Mankin, T. A. Lange, and S. S. Spanier, “The hazards of biopsy in patients with malignant primary bone and soft-tissue tumors,” Journal of Bone and Joint Surgery. Series A, vol. 64, no. 8, pp. 1121–1127, 1982. View at Google Scholar · View at Scopus
  12. E. I. Hauben and P. C. W. Hogendoorn, “Epidemiology of primary bone tumors and economical aspects of bone metastases,” in Bone Cancer. Progression and Therapeutic Approaches, D. Heymann, Ed., pp. 3–8, Academic Press, London, UK, 1st edition, 2009. View at Google Scholar
  13. R. J. Grimer and R. S. Sneath, “Diagnosing malignant bone tumours,” Journal of Bone and Joint Surgery. Series B, vol. 72, no. 5, pp. 754–756, 1990. View at Google Scholar · View at Scopus
  14. P. A. Pizzo and D. G. Poplack, Osteosarcoma. Principles and Practice of Pediatric Oncology, vol. 35, 5th edition, 2006.
  15. R. J. Grimer and T. R. Briggs, “Earlier diagnosis of bone and soft tissue tumours,” Journal of Bone and Joint Surgery, vol. 92-B, no. 11, pp. 1489–1492, 2010. View at Publisher · View at Google Scholar
  16. C. D. M. Fletcher, K. K. Unni, and F. Mertens, WHO Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone, IARC Press, Lyon, France, 2002.
  17. R. Eyre, R. G. Feltbower, E. Mubwandarikwa, T. O. B. Eden, and R. J. Q. McNally, “Epidemiology of bone tumours in children and young adults,” Pediatric Blood and Cancer, vol. 53, no. 6, pp. 941–952, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Kalra, R. J. Grimer, D. Spooner et al., “Radiation induced sarcomas of bone. Factors that affect outcome,” The Journal of Bone and Joint Surgery, vol. 89, pp. 808–813, 2007. View at Google Scholar
  19. National Cancer Intelligence Network, 2010, www.ncin.org.uk/.
  20. R. J. Grimer, S. R. Cannon, A. M. Taminiau et al., “Osteosarcoma over the age of forty,” European Journal of Cancer, vol. 39, no. 2, pp. 157–163, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. H. D. Dorfman and B. Czerniak, “Bone cancers,” Cancer, vol. 75, no. 1, pp. 203–210, 1995. View at Google Scholar · View at Scopus
  22. L. Mascarenhas, S. Siegel, L. Spector et al., “Malignant bone tumours,” SEER AYA Monograph, vol. 8, pp. 97–109, 2002. View at Google Scholar
  23. B. Fuchs and D. J. Pritchard, “Etiology of osteosarcoma,” Clinical Orthopaedics and Related Research, no. 397, pp. 40–52, 2002. View at Google Scholar · View at Scopus
  24. M. F. Hansen, M. Seton, and A. Merchant, “Osteosarcoma in Paget's disease of bone,” Journal of Bone and Mineral Research, vol. 21, supplement, pp. P58–P63, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Bernstein, H. Kovar, M. Paulussen et al., “Ewing's sarcoma family of tumors: current management,” Oncologist, vol. 11, no. 5, pp. 503–519, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. R. F. Riedel, N. Larrier, L. Dodd, D. Kirsch, S. Martinez, and B. E. Brigman, “The clinical management of chondrosarcoma,” Current Treatment Options in Oncology, vol. 10, no. 1-2, pp. 94–106, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. J. V. M. G. Bovée, A.-M. Cleton-Jansen, A. H. M. Taminiau, and P. C. W. Hogendoorn, “Emerging pathways in the development of chondrosarcoma of bone and implications for targeted treatment,” Lancet Oncology, vol. 6, no. 8, pp. 599–607, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. D. Eefting, Y. M. Schrage, M. J. A. Geirnaerdt et al., “Assessment of interobserver variability and histologic parameters to improve reliability in classification and grading of central cartilaginous tumors,” American Journal of Surgical Pathology, vol. 33, no. 1, pp. 50–57, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. H. Gelderblom, P. C. W. Hogendoorn, S. D. Dijkstra et al., “The clinical approach towards chondrosarcoma,” Oncologist, vol. 13, no. 3, pp. 320–329, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. R. J. Grimer, G. Gosheger, A. Taminiau et al., “Dedifferentiated chondrosarcoma: prognostic factors and outcome from a European group,” European Journal of Cancer, vol. 43, no. 14, pp. 2060–2065, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. S. S. Bielack, J.-N. Machatschek, S. Flege, and H. Jürgens, “Delaying surgery with chemotherapy for osteosarcoma of the extremities,” Expert Opinion on Pharmacotherapy, vol. 5, no. 6, pp. 1243–1256, 2004. View at Publisher · View at Google Scholar · View at Scopus
  32. N. Federman, N. Bernthal, F. C. Eilber, and W. D. Tap, “The multidisciplinary management of osteosarcoma,” Current Treatment Options in Oncology, vol. 10, no. 1-2, pp. 82–93, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. National Institute for Health and Clinical Excellence (NICE), “Improving outcomes with children and young people with cancer,” 2005, http://guidance.nice.org.uk/CSGCYP.
  34. J. S. Meyer, H. R. Nadel, N. Marina et al., “Imaging guidelines for children with Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group Bone Tumor Committee,” Pediatric Blood and Cancer, vol. 51, no. 2, pp. 163–170, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. P. Picci, D. Vanel, A. Briccoli et al., “Computed tomography of pulmonary metastases from osteosarcoma: the less poor technique. A study of 51 patients with histological correlation,” Annals of Oncology, vol. 12, no. 11, pp. 1601–1604, 2001. View at Publisher · View at Google Scholar · View at Scopus
  36. M. R. Benz, N. Tchekmedyian, F. C. Eilber, N. Federman, J. Czernin, and W. D. Tap, “Utilization of positron emission tomography in the management of patients with sarcoma,” Current Opinion in Oncology, vol. 21, no. 4, pp. 345–351, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. EURO-E.W.I.N.G 99 treatment manual, 2010, http://euro-ewing.klinikum.uni-muenster.de/.
  38. EURAMOS, 2010, http://www.ctu.mrc.ac.uk/euramos/.
  39. W. F. Enneking, S. S. Spanier, and M. Goodman, “A system for the surgical staging of musculoskeletal sarcoma,” Clinical Orthopaedics and Related Research, vol. 153, pp. 106–120, 1980. View at Google Scholar · View at Scopus
  40. AJCC Cancer Staging Manual, Springer, New York, NY, USA, 6th edition, 2002.
  41. J. A. M. Bramer, J. H. van Linge, R. J. Grimer, and R. J. P. M. Scholten, “Prognostic factors in localized extremity osteosarcoma: a systematic review,” European Journal of Surgical Oncology, vol. 35, no. 10, pp. 1030–1036, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. P. J. Leavey and A. B. Collier, “Ewing sarcoma: prognostic criteria, outcomes and future treatment,” Expert Review of Anticancer Therapy, vol. 8, no. 4, pp. 617–624, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. D. Carrle and S. S. Bielack, “Current strategies of chemotherapy in osteosarcoma,” International Orthopaedics, vol. 30, no. 6, pp. 445–451, 2006. View at Publisher · View at Google Scholar · View at Scopus
  44. A. O. Altuntas, J. Slavin, P. J. Smith et al., “Accuracy of computed tomography guided core needle biopsy of musculoskeletal tumours,” ANZ Journal of Surgery, vol. 75, no. 4, pp. 187–191, 2005. View at Publisher · View at Google Scholar · View at Scopus
  45. C. S. Pramesh, M. S. Deshpande, D. N. Pardiwala, M. G. Agarwal, and A. Puri, “Core needle biopsy for bone tumours,” European Journal of Surgical Oncology, vol. 27, no. 7, pp. 668–671, 2001. View at Publisher · View at Google Scholar · View at Scopus
  46. Royal College of Pathologists Standards and datasets for reporting cancers: dataset for histopathology reports on primary bone tumours, 2010, http://www.rcpath.org/.
  47. SNOMED CT—the language of the NHS Care Records Service, 2007, http://www.connectingforhealth.nhs.uk/publications3769.
  48. I. MacHado, R. Noguera, A. Pellin et al., “Molecular diagnosis of ewing sarcoma family of tumors: a comparative analysis of 560 cases with fish and rt-pcr,” Diagnostic Molecular Pathology, vol. 18, no. 4, pp. 189–199, 2009. View at Publisher · View at Google Scholar
  49. A. H. Aljubran, A. Griffin, M. Pintilie, and M. Blackstein, “Osteosarcoma in adolescents and adults: survival analysis with and without lung metastases,” Annals of Oncology, vol. 20, no. 6, pp. 1136–1141, 2009. View at Publisher · View at Google Scholar · View at Scopus
  50. S. S. Bielack, B. Kempf-Bielack, G. Delling et al., “Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols,” Journal of Clinical Oncology, vol. 20, no. 3, pp. 776–790, 2002. View at Publisher · View at Google Scholar · View at Scopus
  51. C. E. García Franco, W. Torre, A. Tamura et al., “Long-term results after resection for bone sarcoma pulmonary metastases,” European Journal of Cardiothoracic Surgery, vol. 37, no. 5, pp. 1205–1208, 2010. View at Publisher · View at Google Scholar
  52. G. Bacci, S. Ferrari, F. Bertoni et al., “Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli,” Journal of Clinical Oncology, vol. 18, no. 1, pp. 4–11, 2000. View at Google Scholar · View at Scopus
  53. S. J. Cotterill, S. Ahrens, M. Paulussen et al., “Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group,” Journal of Clinical Oncology, vol. 18, no. 17, pp. 3108–3114, 2000. View at Google Scholar · View at Scopus
  54. G. Bacci, C. Forni, A. Longhi et al., “Long-term outcome for patients with non-metastatic Ewing's sarcoma treated with adjuvant and neoadjuvant chemotherapies. 402 patients treated at Rizzoli between 1972 and 1992,” European Journal of Cancer, vol. 40, no. 1, pp. 73–83, 2004. View at Publisher · View at Google Scholar · View at Scopus
  55. M. Paulussen, S. Ahrens, A. W. Craft et al., “Ewing's tumors with primary lung metastases: survival analysis of 114 (European intergroup) cooperative Ewing's sarcoma studies patients,” Journal of Clinical Oncology, vol. 16, no. 9, pp. 3044–3052, 1998. View at Google Scholar · View at Scopus
  56. A. Y. Giuffrida, J. E. Burgueno, L. G. Koniaris, J. C. Gutierrez, R. Duncan, and S. P. Scully, “Chondrosarcoma in the United States (1973 to 2003): an analysis of 2890 cases from the SEER database,” Journal of Bone and Joint Surgery. Series A, vol. 91, no. 5, pp. 1063–1072, 2009. View at Publisher · View at Google Scholar · View at Scopus
  57. E. O. Burgert Jr., M. E. Nesbit, L. A. Garnsey et al., “Multimodal therapy for the management of nonpelvic, localized Ewing's sarcoma of bone: intergroup study IESS-II,” Journal of Clinical Oncology, vol. 8, no. 9, pp. 1514–1524, 1990. View at Google Scholar · View at Scopus
  58. P. Picci, M. Mercuri, S. Ferrari et al., “Survival in high-grade osteosarcoma: improvement over 21 years at a single institution,” Annals of Oncology, vol. 21, no. 6, pp. 1366–1373, 2009. View at Publisher · View at Google Scholar
  59. M. P. Coleman, P. Babb, P. Damiecki et al., Cancer Survival Trends in England and Wales, 1971–1995 Deprivation and NHS Region, The Stationery Office, London, UK, 1999.
  60. C. A. Stiller, S. J. Passmore, M. E. Kroll, P. A. Brownbill, J. C. Wallis, and A. W. Craft, “Patterns of care and survival for patients aged under 40 years with bone sarcoma in Britain, 1980–1994,” British Journal of Cancer, vol. 94, no. 1, pp. 22–29, 2006. View at Publisher · View at Google Scholar · View at Scopus
  61. G. N. Machak, S. I. Tkachev, Y. N. Solovyev et al., “Neoadjuvant chemotherapy and local radiotherapy for high-grade osteosarcoma of the extremities,” Mayo Clinic Proceedings, vol. 78, no. 2, pp. 147–155, 2003. View at Google Scholar · View at Scopus
  62. S. Patel and T. F. DeLaney, “Advanced-technology radiation therapy for bone sarcomas,” Cancer Control, vol. 15, no. 1, pp. 21–37, 2008. View at Google Scholar · View at Scopus
  63. T. F. DeLaney, N. J. Liebsch, F. X. Pedlow et al., “Phase II study of high-dose photon/proton radiotherapy in the management of spine sarcomas,” International Journal of Radiation Oncology Biology Physics, vol. 74, no. 3, pp. 732–739, 2009. View at Publisher · View at Google Scholar · View at Scopus
  64. Y. Chen, F. Ciernik, A. Niemierko et al., “Treatment of unresectable osteosarcoma with proton therapy,” International Journal of Radiation Oncology, vol. 75, no. 3, Abstract 2770, 2009. View at Google Scholar
  65. C. Blattmann, S. Oertel, D. Schulz-Ertner et al., “Non-randomized therapy trial to determine the safety and efficacy of heavy ion radiotherapy in patients with non-resectable osteosarcoma,” BMC Cancer, vol. 10, article no. 96, 2010. View at Publisher · View at Google Scholar
  66. G. Noël, L. Feuvret, R. Ferrand, G. Boisserie, J.-J. Mazeron, and J.-L. Habrand, “Radiotherapeutic factors in the management of cervical-basal chordomas and chondrosarcomas,” Neurosurgery, vol. 55, no. 6, pp. 1252–1260, 2004. View at Publisher · View at Google Scholar · View at Scopus
  67. G. Bacci, E. Palmerini, E. L. Staals et al., “Ewing's sarcoma family tumors of the humerus: outcome of patients treated with radiotherapy, surgery or surgery and adjuvant radiotherapy,” Radiotherapy and Oncology, vol. 93, no. 2, pp. 383–387, 2009. View at Publisher · View at Google Scholar · View at Scopus
  68. A. Schuck, S. Ahrens, M. Paulussen et al., “Local therapy in localized Ewing tumors: results of 1058 patients treated in the CESS 81, CESS 86, and EICESS 92 trials,” International Journal of Radiation Oncology Biology Physics, vol. 55, no. 1, pp. 168–177, 2003. View at Publisher · View at Google Scholar · View at Scopus
  69. M. E. Nesbit Jr., E. A. Gehan, E. O. Burgert Jr. et al., “Multimodal therapy for the management of primary, nonmetastatic Ewing's Sarcoma of bone: a long-term follow-up of the first intergroup study,” Journal of Clinical Oncology, vol. 8, no. 10, pp. 1664–1674, 1990. View at Google Scholar · View at Scopus
  70. A. McTiernan, D. Driver, M. P. Michelagnoli, A. M. Kilby, and J. S. Whelan, “High dose chemotherapy with bone marrow or peripheral stem cell rescue is an effective treatment option for patients with relapsed or progressive Ewing's sarcoma family of tumours,” Annals of Oncology, vol. 17, no. 8, pp. 1301–1305, 2006. View at Publisher · View at Google Scholar · View at Scopus
  71. J. A. M. Bramer, A. A. Abudu, R. J. Grimer, S. R. Carter, and R. M. Tillman, “Do pathological fractures influence survival and local recurrence rate in bony sarcomas?” European Journal of Cancer, vol. 43, no. 13, pp. 1944–1951, 2007. View at Publisher · View at Google Scholar · View at Scopus
  72. I. J. Lewis, M. A. Nooij, J. Whelan et al., “Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European osteosarcoma intergroup,” Journal of the National Cancer Institute, vol. 99, pp. 112–128, 2007. View at Google Scholar
  73. I. J. Cohen, “High-dose methotrexate is effective in osteosarcoma so what is the problem?” Journal of Pediatric Hematology/Oncology, vol. 31, no. 12, pp. 892–894, 2009. View at Google Scholar
  74. S. Ferrari, S. Smeland, M. Mercuri et al., “Neoadjuvant chemotherapy with high-dose ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the italian and Scandinavian Sarcoma Groups,” Journal of Clinical Oncology, vol. 23, no. 34, pp. 8845–8852, 2005. View at Publisher · View at Google Scholar · View at Scopus
  75. S. Ferrari, S. Smeland, A. Bielack et al., Journal of Clinical Oncology, vol. 27, supplement, p. 15s, 2009, abstract 10516, 2009 ASCO Annual Meeting.
  76. E. C. Van Dalen and B. Canargo, “Mthotrexate for high-grade osteosarcoma in children and young adults,” in The Cochrane Collaboration, John Wiley and Sons, New York, NY, USA, 2009. View at Google Scholar
  77. A. M. Goorin, D. J. Schwartzentruber, M. Devidas et al., “Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: pediatric oncology group study POG-8651,” Journal of Clinical Oncology, vol. 21, no. 8, pp. 1574–1580, 2003. View at Publisher · View at Google Scholar · View at Scopus
  78. P. Picci, L. Sangiorgi, B. T. Rougraff, J. R. Neff, R. Casadei, and M. Campanacci, “Relationship of chemotherapy-induced necrosis and surgical margins to local recurrence in osteosarcoma,” Journal of Clinical Oncology, vol. 12, no. 12, pp. 2699–2705, 1994. View at Google Scholar · View at Scopus
  79. P. A. Meyers, C. L. Schwartz, M. D. Krailo et al., “Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival—a report from the children's oncology group,” Journal of Clinical Oncology, vol. 26, no. 4, pp. 633–638, 2008. View at Publisher · View at Google Scholar · View at Scopus
  80. L. Kager, A. Zoubek, U. Pötschger et al., “Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols,” Journal of Clinical Oncology, vol. 21, no. 10, pp. 2011–2018, 2003. View at Publisher · View at Google Scholar · View at Scopus
  81. S. Ferrari, A. Briccoli, M. Mercuri et al., “Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival,” Journal of Clinical Oncology, vol. 21, no. 4, pp. 710–715, 2003. View at Publisher · View at Google Scholar · View at Scopus
  82. B. Kempf-Bielack, S. S. Bielack, H. Jürgens et al., “Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS),” Journal of Clinical Oncology, vol. 23, no. 3, pp. 559–568, 2005. View at Publisher · View at Google Scholar
  83. B. Massimo, G. Giovanni, F. Stefano et al., “Phase 2 trial of two courses of cyclophosphamide and etoposide for relapsed high-risk osteosarcoma patients,” Cancer, vol. 115, no. 13, pp. 2980–2987, 2009. View at Publisher · View at Google Scholar · View at Scopus
  84. A. Muñoz, J. Alfaro, N. Pardo et al., “Long-term results of the Spanish Protocol SO-95 for the treatment of non-metastatic high-grade osteosarcoma of the extremities in children,” Clinical and Translational Oncology, vol. 11, no. 6, pp. 387–392, 2009. View at Google Scholar
  85. M. L. Bernstein, M. Devidas, D. Lafreniere et al., “Intensive therapy with growth factor support for patients with Ewing tumor metastatic at diagnosis: pediatric oncology group/children's cancer group phase II study 9457—a report from the children's oncology group,” Journal of Clinical Oncology, vol. 24, no. 1, pp. 152–159, 2006. View at Publisher · View at Google Scholar · View at Scopus
  86. H. E. Grier, M. D. Krailo, N. J. Tarbell et al., “Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone,” New England Journal of Medicine, vol. 348, no. 8, pp. 694–701, 2003. View at Publisher · View at Google Scholar · View at Scopus
  87. H. Jurgens, U. Exner, H. Gadner et al., “Multidisciplinary treatment of primary Ewing's sarcoma of bone: a 6-year experience of a European Cooperative trial,” Cancer, vol. 61, no. 1, pp. 23–32, 1988. View at Google Scholar · View at Scopus
  88. M. Paulussen, A. W. Craft, I. Lewis et al., “Results of the EICESS-92 study: two randomized trials of Ewing's sarcoma treatment—cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients,” Journal of Clinical Oncology, vol. 26, no. 27, pp. 4385–4393, 2008. View at Publisher · View at Google Scholar · View at Scopus
  89. C. R. Pinkerton, A. Bataillard, S. Guillo, O. Oberlin, B. Fervers, and T. Philip, “Treatment strategies for metastatic Ewing's sarcoma,” European Journal of Cancer, vol. 37, no. 11, pp. 1338–1344, 2001. View at Publisher · View at Google Scholar · View at Scopus
  90. L. M. Wagner, N. McAllister, R. E. Goldsby et al., “Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma,” Pediatric Blood and Cancer, vol. 48, no. 2, pp. 132–139, 2007. View at Publisher · View at Google Scholar · View at Scopus
  91. S. Burdach, A. Meyer-Bahlburg, H. J. Laws et al., “High-dose therapy for patients with primary multifocal and early relapsed Ewing's tumors: results of two consecutive regimens assessing the role of total-body irradiation,” Journal of Clinical Oncology, vol. 21, no. 16, pp. 3072–3078, 2003. View at Publisher · View at Google Scholar · View at Scopus
  92. 2010, http://www.clinicaltrials.gov/.
  93. J. S. Whelan, R. J. Burcombe, J. Janinis, A. M. Baldelli, and A. M. Cassoni, “A systematic review of the role of pulmonary irradiation in the management of primary bone tumours,” Annals of Oncology, vol. 13, no. 1, pp. 23–30, 2002. View at Publisher · View at Google Scholar · View at Scopus
  94. A. Cangir, T. J. Vietti, E. A. Gehan et al., “Ewing's sarcoma metastatic at diagnosis. Results and comparisons of two Intergroup Ewing's Sarcoma Studies,” Cancer, vol. 66, no. 5, pp. 887–893, 1990. View at Google Scholar · View at Scopus
  95. P. J. Leavey, L. Mascarenhas, N. Marina et al., “Prognostic factors for patients with Ewing sarcoma (EWS) at first recurrence following multi-modality therapy: a report from the children's oncology group,” Pediatric Blood and Cancer, vol. 51, no. 3, pp. 334–338, 2008. View at Publisher · View at Google Scholar · View at Scopus
  96. A. M. McTiernan, A. M. Cassoni, D. Driver, M. P. Michelagnoli, A. M. Kilby, and J. S. Whelan, “Improving outcomes after relapse in Ewing's sarcoma: analysis of 114 patients from a single institution,” Sarcoma, vol. 2006, Article ID 83548, 8 pages, 2006. View at Publisher · View at Google Scholar · View at Scopus
  97. M. Cesari, F. Bertoni, P. Bacchini, M. Mercuri, E. Palmerini, and S. Ferrari, “Mesenchymal chondrosarcoma. An analysis of patients treated at a single institution,” Tumori, vol. 93, no. 5, pp. 423–427, 2007. View at Google Scholar · View at Scopus
  98. T. M. Dantonello, C. Int-Veen, I. Leuschner et al., “Mesenchymal chondrosarcoma of soft tissues and bone in children, adolescents, and young adults: experiences of the CWS and COSS study groups,” Cancer, vol. 112, no. 11, pp. 2424–2431, 2008. View at Publisher · View at Google Scholar · View at Scopus
  99. S. Boriani, S. Bandiera, R. Biagini et al., “Chordoma of the mobile spine: fifty years of experience,” Spine, vol. 31, no. 4, pp. 493–503, 2006. View at Publisher · View at Google Scholar · View at Scopus
  100. D. Schulz-Ertner, A. Nikoghosyan, C. Thilmann et al., “Results of carbon ion radiotherapy in 152 patients,” International Journal of Radiation Oncology Biology Physics, vol. 58, no. 2, pp. 631–640, 2004. View at Publisher · View at Google Scholar · View at Scopus
  101. T. F. DeLaney, N. J. Liebsch, F. X. Pedlow et al., “Phase II study of high-dose photon/proton radiotherapy in the management of spine sarcomas,” International Journal of Radiation Oncology Biology Physics, vol. 74, no. 3, pp. 732–739, 2009. View at Publisher · View at Google Scholar · View at Scopus
  102. S. Stacchiotti, A. Marrari, E. Tamborini et al., “Response to imatinib plus sirolimus in advanced chordoma,” Annals of Oncology, vol. 20, no. 11, pp. 1886–1894, 2009. View at Publisher · View at Google Scholar · View at Scopus
  103. E. P. Buddingh, J. K. Anninga, M. I.M. Versteegh et al., “Prognostic factors in pulmonary metastasized high-grade osteosarcoma,” Pediatric Blood and Cancer, vol. 54, no. 2, pp. 216–221, 2010. View at Publisher · View at Google Scholar
  104. H. C. Holscher, J. L. Bloem, H.-J. Van der Woude et al., “Can MRI predict the histopathological response in patients with osteosarcoma after the first cycle of chemotherapy?” Clinical Radiology, vol. 50, no. 6, pp. 384–390, 1995. View at Google Scholar · View at Scopus
  105. A. Abudu, A. M. Davies, P. B. Pynsent et al., “Tumour volume as a predictor of necrosis after chemotherapy in Ewing's sarcoma,” Journal of Bone and Joint Surgery. Series B, vol. 81, no. 2, pp. 317–322, 1999. View at Publisher · View at Google Scholar · View at Scopus
  106. L. H. Aksnes, H. C.F. Bauer, A. A. Dahl et al., “Health status at long-term follow-up in patients treated for extremity localized Ewing sarcoma or osteosarcoma: a Scandinavian Sarcoma Group Study,” Pediatric Blood and Cancer, vol. 53, no. 1, pp. 84–89, 2009. View at Publisher · View at Google Scholar
  107. T. Langer, W. Stöhr, M. Paulides et al., “Prospective multicenter registration of major late sequelae in sarcoma patients using the Late Effects Surveillance System (LESS),” Klinische Padiatrie, vol. 217, no. 3, pp. 176–181, 2005. View at Publisher · View at Google Scholar
  108. M. Bassal, A. C. Mertens, L. Taylor et al., “Risk of selected subsequent carcinomas in survivors of childhood cancer: a report from the childhood cancer survivor study,” Journal of Clinical Oncology, vol. 24, no. 3, pp. 476–483, 2006. View at Publisher · View at Google Scholar · View at Scopus
  109. C. Rodriguez-Galindo, C. Poquette, N. Marina et al., “Hematologic abnormalities and acute myeloid leukemia in children and adolescents administered intensified chemotherapy for the Ewing sarcoma family of tumours,” Journal of Pediatric Hematology/Oncology, vol. 22, no. 4, pp. 321–329, 2000. View at Google Scholar